SLDB FY 2021 Earnings — Solid Biosciences Inc. Revenue & Financial Results | Market Cap Arena

SLDBSolid Biosciences Inc.

$644M

FY 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$14M

Gross Profit

$14M100.0% margin

Operating Income

-$72M-530.5% margin

Net Income

-$72M-530.0% margin

EPS (Diluted)

$-10.14

Cash Flow

Operating Cash Flow

-$78M

Free Cash Flow

-$79M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$232M

Total Liabilities

$24M

Stockholders' Equity

$208M

Cash & Equivalents

$119M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$14M	$0	—
Gross Profit	$14M	-$4M	+447.3%
Operating Income	-$72M	-$86M	+16.4%
Net Income	-$72M	-$88M	+18.2%